Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Current Press Releases

Webcast ImageWebcast
Q2 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call (Live)
07/30/15 at 9:00 a.m. ET
Q2 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Thursday, July 30, 2015 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
Recent Press Releases | Archived Press Releases
DateTitle 
07/15/15Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs. The randomized, blinded, multicenter pivotal study in dogs undergoing knee surger... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 30, 2015, at 9 a.m. ET. The call can be acc... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. Dr. Braunstein brings over 20 years of knowledge and experience from his time both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles advi... 
Printer Friendly Version
05/28/15Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 28, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it completed an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) for administration as a nerve block to provide postsurgical analgesia. Pacira requested an End-of-Review meeti... 
Printer Friendly Version
05/20/15Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 20, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in June: Jefferies 2015 Global Healthcare Conference at 11:30 a.m. ET in New York on Monday, June 1, 2015. Goldman ... 
Printer Friendly Version
05/19/15Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 19, 2015-- Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced data from three studies evaluating the clinical and pharmacoeconomic utility of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain control in patients undergoing colorectal surgery, breast reconstruction and total knee replacement surgery. The data were presented this month at the annual meetings of the World Congress of ... 
Printer Friendly Version
05/07/15Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 7, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference at 8:40 a.m. PT on Thursday, May 14, 2015, in Las Vegas. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
04/30/15Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
EXPAREL® Net Sales up 63% from Prior Year Period Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2015. “With just a two percent... 
Printer Friendly Version
04/16/15Pacira Receives Subpoena from the U.S. Department of Justice
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the ... 
Printer Friendly Version
04/13/15Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 13, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2015 will be released before the market opens on Thursday, April 30, 2015. The Pacira management team will also host a conference call to discuss the company’s financial results and recent and upcoming developments at 9 a.m. ET on Thursday, April 30, 2015. The call can ... 
Printer Friendly Version
04/10/15Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 10, 2015-- Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to manage postsurgical pain following total knee replacement surgery. The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to ... 
Printer Friendly Version
03/26/15Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
-- Results Presented at the 2015 Annual Meeting of the American Academy of Orthopedic Surgeons Find Overall Hospital Cost Savings of More Than $1.5 Million -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 26, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating the benefits associated with the use of EXPAREL® (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patient... 
Printer Friendly Version
03/23/15New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
Data Presented at the 2015 Annual Meeting of the International Anesthesia Research Society PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 23, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of two data presentations on the impact of EXPAREL® (bupivacaine liposome injectable suspension) on postsurgical opioid requirements in patients undergoing hysterectomy or mastectomy. The data were presented during two poster sessi... 
Printer Friendly Version
03/04/15Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 4, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 3:50 p.m. ET on Wednesday, March 11, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by ... 
Printer Friendly Version
03/02/15Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 2, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following a review of its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia. Pacira will immediately schedule an End-of-Review meeting ... 
Printer Friendly Version
02/24/15Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 24, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2014. “We believe 2014 marked another impress... 
Printer Friendly Version
02/11/15Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 11, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced resolution of matters pertaining to certain promotional aspects of EXPAREL detailed in a recent Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP). Pacira announced receipt of the Warning Letter on September 25, 2014 and has since been in constructive discussions with OPDP. ... 
Printer Friendly Version
02/10/15Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 10, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2014, will be released before the market opens on Tuesday, February 24, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, February 24, 2015, at 9 a.m. ET.... 
Printer Friendly Version
01/08/15Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan. 22, 2015, from approximately 4:00 to 6:30 p.m. ET in New York. Members of the Pacira management team, along with clinical experts, will provide an overview of the Company’s future expansion plans for additional EXPAREL® indications, as well as the leading DepoFoam®-based... 
Printer Friendly Version
01/08/15Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL® and total revenue estimates for the fourth quarter and full-year 2014. “We are pleased with the continued success of EXPAREL in the fourth quarter, growth over the previous quarter and growth for the year, which we expect to provide the basis of a strong 2015,” said Dave Stack, president, chief executiv... 
Printer Friendly Version
12/12/14Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 12, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration’s (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product’s storage, instructions of use and use in special popu... 
Printer Friendly Version
11/25/14Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira... 
Printer Friendly Version
11/11/14Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on Wednesday, Nov. 19, 2014, in London. Mr. Stack is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
11/06/14Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
-- Data Presented at the 2014 Annual Meeting of the American Association of Hip and Knee Surgeons Finds Lower Patient-Perceived Pain Scores, Reduced Opioid Consumption and Improved Patient Satisfaction in Patients Who Received EXPAREL – PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in p... 
Printer Friendly Version
10/30/14Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 30, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014. “The third quarter marked another period of consisten... 
Printer Friendly Version
10/27/14New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
--Data from American College of Surgeons Demonstrates Reduced Incidence of Respiratory Depression, Urinary Retention and Fall Risk in Patients Receiving EXPAREL-- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complicat... 
Printer Friendly Version
10/15/14Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call... 
Printer Friendly Version
10/13/14Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
-- Analysis Presented at the 2014 Annual Meeting of the American Society of Anesthesiologists Finds the Safety of EXPAREL Similar to Placebo and Bupivacaine HCl -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 13, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. T... 
Printer Friendly Version
09/25/14Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension). “We take regulatory compliance very seriously and believe that our ... 
Printer Friendly Version
08/05/14Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 8:35 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
07/31/14Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2014. “With nine quarters now under our belt, we are pleased wi... 
Printer Friendly Version
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com